A single dose of giroctocogene fitelparvovec significantly reduced the mean total annual bleeding rate in patients with moderately severe to severe hemophilia A.
Giroctocogene Fitelparvovec Demonstrates Superiority over Factor VIII Prophylaxis in Reducing Annual Bleeding Rate in Patients with Moderate to Severe Hemophilia A
You May Also Like
Where can I buy Tobacco-Free Nicotine products?
February 27, 2025
Ozempic 用於什麼？
February 26, 2025
Global Launch Strategies in the Current Political Climate
February 19, 2025
+ There are no comments
Add yours